ORLANDO, FLORIDA—A decision to delay surgery or radiotherapy for early prostate cancer is in the best interests of most patients according to research presented to the 2013 Genitourinary Cancers Sympo
ORLANDO, FLORIDA—A decision to delay surgery or radiotherapy for early prostate cancer is in the best interests of most patients according to research presented to the 2013 Genitourinary Cancers Symposium by Dr Andrew Loblaw from the Sunnybrook Health Sciences Centre in Toronto who talked with Peter Goodwin about his group’s finding that the rate of “migration” of Gleason grade — representing the gradual progression of the disease — was gradual, with no more than a third of patients developing a form of the disease requiring treatment within ten years: so the remaining patients can be spared side effects from treatment.
LISTEN
[audio:https://www.audiomedica.com/podcasting/oncology/130310AndrewLoblawAJOPODCASTLoRes.mp3]
Related Episodes
Adjuvant Chemotherapy Extends Life in Locally Advanced Bladder Cancer
ORLANDO—Adjuvant chemotherapy was found to extend life in patients with locally advanced bladder cancer in research reported to the 2015 Genitourinary Cancers Symposium. Matt Galsky MD from the Tisch
Castration-resistant prostate cancer with bone metastases: long follow up shows radium is safe as well as effective
SAN FRANCISCO—New research has shown the alpha-emitting drug radium 233 to be a “benign” therapy with no major toxicities — while effectively targeting bone metastatic disease and increasi
Enzalutamide in metastatic castration resistant prostate cancer: over 75s benefit too
ORLANDO, FLORIDA—Men over 75 were safely and effectively treated for their metastatic castration-resistant prostate cancer with the androgen receptor inhibitor enzalutamide in the Phase III AFFIRM stu